Patty Taneja, MS, LCGC discusses an Illumina clinical experience paper. The primary goal of this study was to provide clinically relevant information that could be used for patient counseling. This study, which includes over 86,000 clinical samples, revealed some important demographic changes including: more patients undergoing testing in the first trimester and lower test positive rates for chromosomes 21 and 18. Additionally, test modifications implemented in the Redwood City, CA CLIA laboratory since the Futch et al1 study have facilitated significant improvements in key performance indicators such as a refinement in borderline result classification and reduction of aneuploidy suspected cases; a significant reduction in turn-around times; and a lower technical cancellation rate.2 The observed sensitivity and specificities were calculated for this clinical population and used to develop a Positive Predictive Value (PPV) tool. Ms. Taneja reviews what these demographic and performance indicator changes mean and how clinicians can best use the Positive Predictive Value (PPV) tool for patient counseling. Webinar at a glance • Study provides clinically relevant information for appropriate patient counseling • Demographics and test metrics reviewed for over 86000 clinical cases • Development of PPV counseling tool • Review of how clinicians can best use the tool Presenter: Patty Taneja, MS, LCGC View related videos Integrating Non-invasive DNA Testing (NIDT) into the Prenatal Testing Paradigm: Diana W. Bianchi, MD https://www.youtube.com/watch?v=BWd9WNZ_3QM View related article Taneja PA, Snyder HL, de Feo E, et al. Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85,000 cases. Prenat Diagn. 2015;doi:10.1002/pd.4766. http://onlinelibrary.wiley.com/doi/10.1002/pd.4766/abstract?campaign=wolacceptedarticle References 1. Futch T, Spinosa J, Bhatt S, et al. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn 2013;33(6):569-74. 2. Taneja PA, Snyder HL, de Feo E, et al. Noninvasive prenatal testing in the general obstetric population: clinical performance and in over 85,000 cases. Prenat Diagn. 2015;doi:10.1002/pd.4766 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaIncconsiderations